ArticleJournal of hepatocellular carcinoma2026
Development and Validation of a Nomogram for Predicting Response to TACE Combined with Lenvatinib and Anti-PD-1 Therapy in Unresectable Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis for unresectable hepatocellular carcinoma (u-HCC) patients receiving monotherapy remains poor, driving the need for more effective combination therapies. Although transarterial chemoembolization (TACE) combined with targeted therapy and immunotherapy shows promising efficacy, robust biomarkers are needed to identify patients most likely to benefit. This study aimed to develop and validate a nomogram to predict treatment response in u-HCC patients receiving triple therapy. Methods: We conducted a multicenter retrospective study including u-HCC patients who received triple therapy between January 2021 and June 2024. Patients from one hospital (n=91) were assigned to the training cohort, and those from two other centers (n=54) constituted the external validation cohort. Treatment response was evaluated according to mRECIST criteria. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of the objective response rate (ORR). A nomogram integrating clinical and imaging features was constructed and evaluated using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA). Results: Multivariate analysis identified six independent predictors of ORR: alpha-fetoprotein (AFP) level, lymphocyte-to-monocyte ratio (LMR), portal vein tumor thrombus (PVTT), tumor number, irregular arterial phase enhancement, and tumor rupture. The combined nomogram, integrating clinical and imaging features, demonstrated superior predictive performance, with AUCs of 0.915 (95% CI: 0.838-0.963) in the training cohort and 0.933 (95% CI: 0.831-0.983) in the validation cohort. Calibration curves showed good agreement between predicted and observed probabilities, and DCA confirmed the clinical utility of the model. The incidence of adverse events did not differ significantly among treatment regimens (P > 0.05). Conclusion: We developed and validated a non-invasive nomogram that integrates readily available clinical and imaging features to effectively predict treatment response to triple therapy in u-HCC patients. This tool holds potential for personalizing treatment strategies and improving prognostic assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.